The drug is being marketed in the United States under the brand name Linzess. It was approved by the Food and Drug Administration earlier this year as a treatment for adults suffering from irritable bowel syndrome with constipation. Linzess is a trade name for linaclotide.
It has been estimated that irritable bowel syndrome afflicts 30 million to 40 million Americans. Some stock analysts project that the Ironwood drug could attain blockbuster status — ringing up sales of more than $1 billion a year worldwide — within a decade, a recent Globe story noted.